Search clinical trials for: Outcome

Total 1162 results

Clinica Universidad de Navarra, Universidad de...

Unknown

Phase I-II Study of Intratumoral Urelumab Combined With Nivolumab in Patients With Solid Tumors (INTRUST)

Neoplasms

Spain
Alona Zer
Bristol-Myers Squibb

Unknown

Nivolumab and Ipilimumab in Classical Kaposi Sarcoma (CKS)

Classic Kaposi Sarcoma

Israel
CatalYm GmbH

Recruiting

Neoadjuvant Immunotherapy in Combination With the Anti-GDF-15 Antibody Visugromab (CTL-002) for Treatment of Muscle Invasive Bladder Cancer

Adult Solid Tumor | Bladder Cancer

Italy
Dana-Farber Cancer Institute
Gateway for Cancer Research

Recruiting

Study of Nivolumab and Ipilimumab in Children and Young Adults With INI1-Negative Cancers

Epithelioid Sarcoma | Atypical Teratoid/Rhabdoid Tumor | Malignant Rhabdoid Tumor | Rhabdoid Tumor of the Kidney | Chordoma (Poorly Differentiated or De-differentiated) | Other INI1 Negative Tumors (With PI Approval) | Other SMARCA4-deficient Malignant Tumors (With PI Approval)

United States
European Organisation for Research and Treatment...

Terminated

Combination of Chemoradiation With Immunotherapy in Inoperable œsophageal Cancer (CRUCIAL)

Inoperable œsophageal Cancer

Spain, France
Bristol-Myers Squibb

Completed

A Safety Trial of Nivolumab in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Progressed During or After Receiving At Least One Prior Chemotherapy Regimen (CheckMate153)

Non Small Cell Lung Cancer (NSCLC)

United States, Canada
Abramson Cancer Center of the University of Pennsylvania

Terminated

Nivolumab and Ipilimumab in Mucinous Colorectal and Appendiceal Tumors

Mucinous Adenocarcinoma of the Rectum | Mucinous Adenocarcinoma of the Colon

United States
H. Lee Moffitt Cancer Center and Research Institute
Bristol-Myers Squibb; Celgene Corporation

Completed

Avadomide (CC-122) in Combination With Nivolumab in Advanced Melanoma

Melanoma

United States
National Cancer Centre, Singapore
National University Hospital, Singapore; Johns Hopkins Singapore

Terminated

Study of Nivolumab Verses Nivolumab and Ipilimumab Combination in EGFR Mutant Non-small Cell Lung Cancer

Non-Small Cell Lung Cancer

Singapore
Bristol-Myers Squibb

Completed

A Study of Nivolumab in Participants With Squamous Cell Carcinoma of the Head & Neck (SCCHN) - Patient Reported Outcomes (PRO) (VOLUME-PRO)

Squamous Cell Carcinoma of the Head and Neck

United States
Infinity Pharmaceuticals, Inc.

Active, not recruiting

A Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IPI-549

Advanced Solid Tumors (Part A/B/C/D) | Non-small Cell Lung Cancer (Part E) | Melanoma (Part E) | Squamous Cell Cancer of the Head and Neck (Part E) | Triple Negative Breast Cancer (Part F) | Adrenocortical Carcinoma (Part G) | Mesothelioma (Part G) | High-circulating Myeloid-derived Suppressor Cells...

United States
NYU Langone Health
Bristol-Myers Squibb; Daiichi Sankyo, Inc.

Completed

Study of DS-8273a With Nivolumab in Unresectable Stage III or Stage IV Melanoma

Melanoma

United States
Eli Lilly and Company
Bristol-Myers Squibb

Completed

A Study of Galunisertib (LY2157299) in Combination With Nivolumab in Advanced Refractory Solid Tumors and in Recurrent or Refractory NSCLC, or Hepatocellular Carcinoma

Solid Tumor | Hepatocellular Carcinoma Recurrent | Non-Small Cell Lung Cancer Recurrent

Spain, United States
Kidney Cancer Research Bureau

Unknown

Nivolumab and Ipilimumab in T1aN0M0 Renal Cell Carcinoma Patients Ineligible for Surgical Treatment.

Renal Cell Carcinoma

Russian Federation
University Hospital Heidelberg

Unknown

Nivolumab/Ipilimumab in Second Line CUP-syndrome (CheCUP)

Cancer of Unknown Primary Site

Germany
howard safran
The Miriam Hospital; Rhode Island Hospital

Terminated

Advanced Non-Small Cell Lung Cancer Progressing After at Least One Prior Therapy For Metastatic Disease

NSCLC | Lung Cancer | Metastatic Lung Cancer | Non-small Cell Lung Cancer

United States
University Hospital, Tours

Completed

Study of the Concentration-effect Relationship of Nivolumab in Patients With Kidney or Lung Cancer (NIVEAL)

Kidney Cancer | Lung Cancer

France
Sidney Kimmel Comprehensive Cancer Center at Johns...
Bristol-Myers Squibb

Terminated

Phase 2 Study of Nivolumab in Solid Tumors Induced by Prior Radiation Exposure

Solid Tumors Induced by Prior Radiation Exposure

United States
University of Washington
National Cancer Institute (NCI)

Terminated

Nivolumab and Plinabulin in Treating Patients With Stage IIIB-IV, Recurrent, or Metastatic Non-small Cell Lung Cancer

Recurrent Non-Small Cell Lung Carcinoma | EGFR Activating Mutation | Stage IV Non-Small Cell Lung Cancer AJCC v7 | ALK Gene Translocation | Stage IIIB Non-Small Cell Lung Cancer AJCC v7 | ROS1 Gene Translocation

United States
University of Texas Southwestern Medical Center

Withdrawn

Nivolumab Based Immunotherapy for Treatment of High Grade Cervical Dysplasia

Cervix Uteri--Diseases
Hospices Civils de Lyon

Unknown

Immune Modulation Study in Patients With Metastatic Melanoma Treated With Anti-PD1 Monoclonal Antibodies (PAIR)

Metastatic Melanoma

France
Cancer Institute and Hospital, Chinese Academy...
Biotech Pharmaceutical Co., Ltd.

Unknown

Nimotuzumab Plus Docetaxel and Capecitabine Versus Docetaxel and Capecitabine in the Treatment of Breast Cancer Patients

Breast Cancer

China
Samsung Medical Center

Unknown

Afatinib Plus Nimotuzumb for NSCLC

NSCLC

Korea, Republic of
Otsuka Pharmaceutical Co., Ltd.

Completed

A Trial to Investigate the Efficacy and Safety of Orally Administered Tolvaptan (OPC-41061) in Patients With Chronic Renal Failure Undergoing Hemodialysis or Hemodiafiltration

Chronic Renal Failure

Japan
Lee's Pharmaceutical Limited
Zhaoke (Guangzhou) Pharmaceutical Limited

Completed

Bioequivalence Study of Azilsartan Tablets in Chinese Healthy Volunteers

Bioequivalence of Two Azilsartan Formulations

Hong Kong
Ruijin Hospital

Not yet recruiting

Neoadjuvant Chemotherapy Plus Sequential Immune Checkpoint Inhibitor (ICI) Therapy in Locally Advanced Colon Cancer (NeoCHIC)

Colon Cancer

China
Xiangdong Cheng

Recruiting

Nivolumab Combined With SOX Used in the Perioperative Treatment

Gastric Cancer | Immune Suppression

China
Hospital das Clínicas de Ribeirão Preto
Bristol-Myers Squibb; Fundação de Amparo à Pesquisa do Estado de São Paulo

Recruiting

CLARA: Somatic and Germline Mechanisms That Impact Renal Cancer Immunotherapy

Renal Cancer Metastatic

Brazil
Asylia Diagnostics BV

Recruiting

Open-label, Uncontrolled, Non-Interventional, Retrospective Study to Evaluate Molecular Determinants of Outcome to the Immune Checkpoint Inhibitors (Anti-PD-1/Anti-PD-L1 Monoclonal Antibodies) Treatment for Solid Tumors

Melanoma | Lung Cancer

Belgium
University College, London
Bristol-Myers Squibb

Active, not recruiting

Nivolumab and Ipilimumab Treatment in Prostate Cancer With an Immunogenic Signature

Prostate Cancer

United Kingdom
Sarah Sammons, MD
Bristol-Myers Squibb; Duke University

Terminated

Neoadjuvant Immunotherapy in Brain Metastases

Brain Metastases, Adult

United States
Philogen S.p.A.

Active, not recruiting

F16IL2 in Combination With Nivolumab in Patients With Non-small Cell Lung Cancer (Nivokin)

Non-small Cell Lung Cancer (NSCLC)

Switzerland
Transgene

Terminated

A Trial to Evaluate the Safety and Efficacy of the Combination of the Oncolytic Immunotherapy Pexa-Vec With the PD-1 Receptor Blocking Antibody Nivolumab in the First-line Treatment of Advanced Hepatocellular Carcinoma (HCC)

Hepatocellular Carcinoma (HCC)

France
Bristol-Myers Squibb

Withdrawn

Neoadjuvant Nivolumab+Ipilimumab Followed by Adjuvant Nivolumab or Neoadjuvant Nivolumab+Ipilimumab Followed by Adjuvant Observation Compared With Adjuvant Nivolumab in Treatment-Naive High-risk Melanoma Participants (CheckMate 7UA)

Melanoma

France, Italy, Poland, United States, Brazil, Spain, Australia, Denmark, Germany, Austria, Netherlands, Russian Federation, Belgium, United Kingdom, Sweden, Switzerland
Shanghai Zhongshan Hospital

Unknown

Efficacy and Safety of Anlotinib Hydrochloride Combined With Nivolumab in the Treatment of Gastric and Esophageal Cancer (OASIS)

Gastric Adenocarcinoma | Esophageal Squamous Cell Carcinoma
University Hospital Muenster
BioMérieux

Recruiting

Biomarker-guided Intervention to Prevent Acute Kidney Injury (BigpAK-2)

Acute Kidney Injury

Spain, France, Germany, Italy, Netherlands, United Kingdom, Belgium, Switzerland
Ya-Wei Xu

Completed

Clinical Characteristics and Predictors of Adverse Outcomes in HFpEF

Heart Failure With Preserved Ejection Fraction
Flame Biosciences

Withdrawn

FL-101 in Surgically Resectable Non-Small Cell Lung Cancer

Non-Small Cell Lung Cancer
Dana-Farber Cancer Institute
Bristol-Myers Squibb; Exelixis

Completed

A Phase II Study of Nivolumab in Combination With Cabozantinib for Metastatic Triple-negative Breast Cancer

Breast Cancer

United States
Gilead Sciences

Completed

Study to Evaluate the Efficacy and Safety of Andecaliximab Combined With Nivolumab Versus Nivolumab Alone in Adults With Unresectable or Recurrent Gastric or Gastroesophageal Junction Adenocarcinoma

Gastric Adenocarcinoma | Gastroesophageal Junction Adenocarcinoma

Spain, United States, Hungary, United Kingdom, Italy, France, Poland, Australia, Belgium
Bausch Health Americas, Inc.

Completed

12-Week Study of Plecanatide for CIC (The National CIC3 Study) (CIC)

Chronic Idiopathic Constipation

United States
Rennes University Hospital

Completed

Nivolumab and Ipilimumab Versus Chimiotherapy in First Line Treatment in PS 2 or Elderly in Advanced NSCLC Patients (eNERGY)

Advanced Non Small Cell Lung Cancer

France
PrECOG, LLC.
Bristol-Myers Squibb

Completed

Phase Ib Feasibility Trial of Neoadjuvant Nivolumab/Lirilumab in Cisplatin-Ineligible Muscle-Invasive Bladder Cancer (PrE0807)

Bladder Cancer

United States
Grupo Español Multidisciplinar de Melanoma
Bristol-Myers Squibb

Completed

Trial of Nivolumab in Combination With Ipilimumab in Subjects With Previously Untreated Metastatic Uveal Melanoma (GEM1402)

Uveal Melanoma

Spain
Pfizer
Bristol-Myers Squibb

Completed

Study of Binimetinib + Nivolumab Plus or Minus Ipilimumab in Patients With Previously Treated Microsatellite-stable (MSS) Metastatic Colorectal Cancer With RAS Mutation

MSS | RAS-mutant Colorectal Cancer

United States, Spain, Belgium, United Kingdom, Netherlands
Bristol-Myers Squibb

Completed

An Investigational Immunotherapy Study of BMS-986310 Administered Alone and in Combination With Nivolumab in Patients With Advanced Solid Tumors

Advanced Cancer

United States, Belgium, Canada
MedImmune LLC

Completed

A Phase 1/2, Open-label Study to Evaluate the Safety and Antitumor Activity of MEDI0680 (AMP-514) in Combination With Durvalumab Versus Nivolumab Monotherapy in Participants With Select Advanced Malignancies

Kidney Cancer | Clear Cell Renal Cell Carcinoma | Select Advanced Malignancies

United States, France, Canada, United Kingdom, Netherlands, Australia
Chang Gung Memorial Hospital

Unknown

WGA in Platinum-refractory HNSCC Underwent Nivolumab

HNSCC

Taiwan
Spanish Lung Cancer Group

Completed

Nivolumab in the Real World: Analysis of the Expanded Use in Spanish Patient (NIVEX)

Non Small Cell Lung Cancer

Spain
Koç University
Marmara University; Sultan Abdulhamid Han Training and Research Hospital, Istanbul... and other collaborators

Recruiting

Sleep Disorders in Patients With Suspected Lung Cancer Before and After Thoracic Surgery

Lung Cancer

Turkey

Search clinical trials for: Outcome

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Pakistan

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations